Human Epididymis Protein 4 (Serial Monitor)
Use
The Human Epididymis Protein 4 (HE4) test is used for serial monitoring in patient management, particularly in the context of ovarian cancer. This biomarker is elevated in patients with epithelial ovarian cancer and is used to monitor disease progression and aid physicians in evaluating a patient's response to treatment. The consistent use of a single assay methodology is recommended for accurate trend analysis in serial monitoring.
Special Instructions
Patients' Social Security numbers must be submitted for monitoring. Values obtained from different assay methods should not be used interchangeably in serial testing. Biotin supplementation can interfere with test results; therefore, patients should cease biotin intake 72 hours prior to sample collection.
Limitations
Results from this test cannot be interpreted as absolute evidence for the presence or absence of malignant disease. Different assay kits or methodologies may yield non-comparable results, highlighting the importance of using a consistent method for serial testing.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 55180-4
- 80563-0
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Patients should not consume biotin supplements at least 72 hours prior to sample collection.